Outcome of treatment of multiple myeloma patients with bortezomib-based regimens compared to vincristine,doxorubicin and dexamethasone (VAD) regimen / (Record no. 66278)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03618cam a2200349 a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | EG-GiCUC |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250223032008.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 180521s2017 ua dh f m 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | EG-GiCUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GiCUC |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| 049 ## - LOCAL HOLDINGS (OCLC) | |
| Holding library | Deposite |
| 097 ## - Thesis Degree | |
| Thesis Level | M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Classification number | Cai01.19.04.M.Sc.2017.Ma.O |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Maha Alaa Eldin Abdelfatah |
| 245 10 - TITLE STATEMENT | |
| Title | Outcome of treatment of multiple myeloma patients with bortezomib-based regimens compared to vincristine,doxorubicin and dexamethasone (VAD) regimen / |
| Statement of responsibility, etc. | Maha Alaa Eldin Abdelfatah ; Supervised Mohamed Abdelmooti , Omar Elfarouk Osman Zaki , Mosaad Mahmoud Elgammal |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | نتائج علاج الميلوما المتعددة باستخدام البروتوكولات المحتوية على البورتزيماب مقارنة باستخدام البروتوكول المحتوي على الفينكرستين والدوكسوربسين والديكساميثازون |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | Cairo : |
| Name of publisher, distributor, etc. | Maha Alaa Eldin Abdelfatah , |
| Date of publication, distribution, etc. | 2017 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 121 P. : |
| Other physical details | charts , facsimiles ; |
| Dimensions | 25cm |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Oncology (Medical ) |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Objective: Compare outcome of treatment of Bortezomib-based regimens versus VAD regimen (Vincristine, Doxorubicin, Dexamethazone) in multiple myeloma patients treated in The Medical Oncology departments of both National Cancer Institute (NCI) and Nasser Institute from January 2011 till December 2015). Methods:This study was performed retrospectively on 89 MM patientstreated at The Medical Oncology departments of both National Cancer Institute (NCI) and Nasser Institute from January 2011 till December 2015.All patients were evaluated for different responses with different lines of treatment (VAD versus Bortezomib based regimens) which correlated with progression free survival (PFS) and overall survival (OS). Also, the different prognostic factors: age, sex, clinical presentation, albumin, LDH, creatinine,B2 microglobulin, ISS, Durie Salmon Staging and ASCT which correlated with different lines of treatment, PFS and OS. Results: The age of patients ranged between 32 years to 76 years and the mean age was 51.1+/-7.4 years. It included 65.2% males and 34.8% females with male to female ratio 1.87:1. Bony pains were the most common clinical manifestation of patients in our study (44.9%) followed by bony masses (22.5%), fractures (16.9%), pallor (7.9%), neurological symptoms (5.6%) and finally oliguria (2.2%).Bortezomib based regimens have better overall response rate (ORR)({u2265}PR)( p value 0.031), progression free survival PFS(p value 0.004) and disease free survival DFS(p value 0.013) as 1st line treatment compared to VAD regimen. Also in previously treated patients bortezomib based regimens showed better progression free survival PFS(p value 0.039) compared to VAD regimen. There was significant relation between age (p value 0.001&<0.001) and ASCT (p value 0.001&0.034) with PFS and OS respectively, while other factors was not significant including (sex, clinical presentation, B2 microglobulin, creatinine, LDH, albumin, ISS, Durie Salmon Staging) |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Additional physical form available note | Issued also as CD |
| 653 #4 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Bortezomib based regimens |
| 653 #4 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Multiple Myeloma |
| 653 #4 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | VAD regimen |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mohamed Abdelmooti , |
| Relator term | |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mosaad Mahmoud Elgammal , |
| Relator term | |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Omar Elfarouk Osman Zaki , |
| Relator term | |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="http://172.23.153.220/th.pdf">http://172.23.153.220/th.pdf</a> |
| 905 ## - LOCAL DATA ELEMENT E, LDE (RLIN) | |
| Cataloger | Nazla |
| Reviser | Revisor |
| 905 ## - LOCAL DATA ELEMENT E, LDE (RLIN) | |
| Cataloger | Shimaa |
| Reviser | Cataloger |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Source of classification or shelving scheme | Not for loan | Home library | Current library | Date acquired | Full call number | Barcode | Date last seen | Koha item type | Copy number |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 11.02.2024 | Cai01.19.04.M.Sc.2017.Ma.O | 01010110075086000 | 22.09.2023 | Thesis | ||
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | مخـــزن الرســائل الجـــامعية - البدروم | 11.02.2024 | Cai01.19.04.M.Sc.2017.Ma.O | 01020110075086000 | 22.09.2023 | CD - Rom | 75086.CD |